{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-007322","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.765560+00:00","generated_at":"2026-06-14T12:21:12.991758+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Palatin presents preclinical data on PL8177 in diabetic nephropathy; Phase 2 BREAKOUT study enrolling","bullets":["PL8177 preserved podocyte count and WT1 expression in diabetic rats vs. vehicle.","Glomerular hypertrophy trended toward reduction in PL8177-treated kidneys.","Data presented at International Podocyte Conference, May 24-26, 2023 in Philadelphia.","Phase 2 BREAKOUT study (bremelanotide) for diabetic kidney disease now enrolling (NCT05709444).","CEO cites melanocortin system potential for new inflammatory disease treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-007322","json":"https://secwatch.observer/filing/0001654954-23-007322.json","markdown":"https://secwatch.observer/filing/0001654954-23-007322.md","text":"https://secwatch.observer/filing/0001654954-23-007322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423007322/0001654954-23-007322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423007322/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T12:21:12.991758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}